Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Key Benefits Observed in Clinical Trials Treatment of Erythropoietic Protoporphyria (EPP): MT-1 (Afamelanotide) is FDA-approved for use in patients with EPP, a rare genetic disorder that causes extreme photosensitivity, leading to severe pain and skin damage upon light exposure
Rockerbie N, Solomon AR, Woo TY, et al
Sensing of redox status by TRP channels
PWA mice were placed on their cage grid, and pictures of the interscapular brown adipose tissue area were taken 6 h after acute administration with GLP1/E, GLP1/GIP, or GLP1/GIP/Glucagon (10 nmol/kg)
US$ 22.16
US$ 23.77
/assets/production/practices/3280152d22c7599df4208c7f13bd6f106ba2a939/images/2788239.jpeg)
US$ 23.18
US$ 23.03
